CA3129782A1 - Improved survival of human cells differentiated <i>in vitro</i> by prpf31 gene expression knockdown - Google Patents

Improved survival of human cells differentiated <i>in vitro</i> by prpf31 gene expression knockdown Download PDF

Info

Publication number
CA3129782A1
CA3129782A1 CA3129782A CA3129782A CA3129782A1 CA 3129782 A1 CA3129782 A1 CA 3129782A1 CA 3129782 A CA3129782 A CA 3129782A CA 3129782 A CA3129782 A CA 3129782A CA 3129782 A1 CA3129782 A1 CA 3129782A1
Authority
CA
Canada
Prior art keywords
cells
differentiated
nucleic acid
vitro
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3129782A
Other languages
English (en)
French (fr)
Inventor
Charles E. Murry
Sarah DUPRAS
John LAMACCHIA
James FUGATE
William Robb MACLELLAN
Lil Pabon
Scott THIES
Hiroshi Tsuchida
Stephanie A. TUCK
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Original Assignee
University of Washington
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington filed Critical University of Washington
Publication of CA3129782A1 publication Critical patent/CA3129782A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A61K35/545—Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0657—Cardiomyocytes; Heart cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/45—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from artificially induced pluripotent stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3129782A 2019-03-15 2020-03-13 Improved survival of human cells differentiated <i>in vitro</i> by prpf31 gene expression knockdown Pending CA3129782A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962818979P 2019-03-15 2019-03-15
US62/818,979 2019-03-15
PCT/US2020/022679 WO2020190739A1 (en) 2019-03-15 2020-03-13 Improved survival of human cells differentiated in vitro by prpf31 gene expression knockdown

Publications (1)

Publication Number Publication Date
CA3129782A1 true CA3129782A1 (en) 2020-09-24

Family

ID=72520464

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3129782A Pending CA3129782A1 (en) 2019-03-15 2020-03-13 Improved survival of human cells differentiated <i>in vitro</i> by prpf31 gene expression knockdown

Country Status (7)

Country Link
US (1) US20220152278A1 (enExample)
EP (1) EP3937956A4 (enExample)
JP (1) JP2022525193A (enExample)
CN (1) CN113710258A (enExample)
AU (1) AU2020241251A1 (enExample)
CA (1) CA3129782A1 (enExample)
WO (1) WO2020190739A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4356931A4 (en) * 2021-06-16 2025-07-16 Chigenovo Co Ltd VARIANT OF PRPF31 AND ITS USE
US20250082689A1 (en) * 2021-07-21 2025-03-13 University Of Washington Compositions and methods for enhancing cardiomyocyte transplant engraftment
JP2025534556A (ja) * 2022-10-21 2025-10-16 バイオジェン・エムエイ・インコーポレイテッド 網膜色素変性症を治療するための組成物及び方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006507841A (ja) * 2002-11-14 2006-03-09 ダーマコン， インコーポレイテッド 機能的ｓｉＲＮＡおよび超機能的ｓｉＲＮＡ
US7875451B2 (en) * 2006-01-19 2011-01-25 The University Of Washington Formulation to improve survival of transplanted cells
AU2008204541B2 (en) * 2007-01-09 2014-07-10 Lead Pharma Cel Models Ip B.V. Provision of new cardiomyocyte progenitor cells and cardiomyocytes derived therefrom
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
AU2008346801A1 (en) * 2007-12-31 2009-07-16 Nanocor Therapeutics, Inc. RNA interference for the treatment of heart failure
EP2510087A2 (en) * 2009-12-11 2012-10-17 The Brigham and Women's Hospital, Inc. Pathogen restriction factors
EP4721752A2 (en) * 2011-12-30 2026-04-08 Cellscript, Llc Herstellung und verwendung von in vitro-synthetisierter ssrna zur einführung in säugetierzellen zur induktion einer biologischen oder biochemischen wirkung
PT3265568T (pt) * 2015-03-06 2020-08-20 Massachusetts Eye & Ear Infirmary Terapias de aumento de genes para a degeneração hereditária da retina causada por mutações no gene prpf31
FR3058160A1 (fr) * 2016-10-28 2018-05-04 Universite Pierre Et Marie Curie - Paris 6 (Upmc) Procede de differenciation de cellules souches pluripotentes en cardiomyocytes
JP7333271B2 (ja) * 2017-03-15 2023-08-24 ユニヴァーシティ オブ ワシントン 心筋細胞の成熟および生着を増強するための方法および組成物

Also Published As

Publication number Publication date
EP3937956A1 (en) 2022-01-19
JP2022525193A (ja) 2022-05-11
US20220152278A1 (en) 2022-05-19
AU2020241251A1 (en) 2021-10-07
CN113710258A (zh) 2021-11-26
WO2020190739A1 (en) 2020-09-24
EP3937956A4 (en) 2022-12-28

Similar Documents

Publication Publication Date Title
JP6821908B2 (ja) 哺乳動物種における誘導組織再生のための組成物および方法
JP7419347B2 (ja) 哺乳動物細胞における組織再生の誘導及びセノリシスのための改良された方法
US20240368541A1 (en) Methods of generating mature corneal endothelial cells
US10071138B2 (en) Compositions and methods for modulating stem cells and uses thereof
US8815593B2 (en) Induction of human embryonic stem cell derived cardiac pacemaker or chamber-type cardiomyocytes by manipulation of neuregulin signaling
US20250216377A1 (en) Compositions and methods for detecting cardiotoxicity
US20220152278A1 (en) Improved survival of human cells differentiated in vitro by prpf31 gene expression knockdown
US10443044B2 (en) Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds
JP2011522520A (ja) 細胞の脱分化を行う方法
US20180042969A1 (en) Compositions and methods for the reprogramming of cells into cardiomyocytes
US20130202649A1 (en) Activation of innate immunity for nuclear reprogramming of somatic cells
US20240392252A1 (en) Generating cardiac progenitor cells from pluripotent stem cells using isoxazole or isoxazole like compounds
US20200306296A1 (en) Induced tissue regeneration using extracellular vesicles
WO2012075027A1 (en) Embedded chimeric peptide nucleic acids for generation of induced pluripotent stem cells
CN117500940A (zh) 原钙粘蛋白在诊断和治疗癌症的方法中的用途
US12173322B2 (en) Genome-edited induced pluripotent stem cells, and cells derived therefrom, and uses thereof
HK40096970A (zh) 产生成熟角膜内皮细胞的方法

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250902

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251103

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251231